KCG Holdings Inc. increased its stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 4.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,537 shares of the biotechnology company’s stock after buying an additional 1,820 shares during the period. KCG Holdings Inc.’s holdings in Brainstorm Cell Therapeutics were worth $177,000 as of its most recent filing with the SEC.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) traded down 0.6736% during mid-day trading on Monday, reaching $4.2909. 8,397 shares of the company’s stock were exchanged. The stock’s market cap is $80.39 million. The company has a 50-day moving average of $4.46 and a 200-day moving average of $3.99. Brainstorm Cell Therapeutics Inc. has a 52-week low of $2.06 and a 52-week high of $5.18.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Monday, May 15th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.20. Equities research analysts anticipate that Brainstorm Cell Therapeutics Inc. will post ($0.79) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Bought by KCG Holdings Inc.” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://stocknewstimes.com/2017/08/07/brainstorm-cell-therapeutics-inc-nasdaqbcli-shares-bought-by-kcg-holdings-inc.html.
Several analysts recently commented on the stock. Maxim Group set a $8.00 target price on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a report on Saturday, July 22nd. ValuEngine raised shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 22nd.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Want to see what other hedge funds are holding BCLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI).
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
